LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

Search

Amgen Inc

Geschlossen

BrancheGesundheitswesen

356.59 1.23

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

344.71

Max

354.3

Schlüsselkennzahlen

By Trading Economics

Einkommen

486M

1.8B

Verkäufe

-1.3B

8.6B

KGV

Branchendurchschnitt

23.989

50.958

EPS

5.15

Dividendenrendite

2.86

Gewinnspanne

21.107

Angestellte

31,500

EBITDA

-1.2B

3.9B

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+1.69% upside

Dividenden

By Acuity

Dividendenrendite

Branchendurchschnitt

2.86%

2.41%

Nächstes Ergebnis

4. Aug. 2026

Nächste Dividendenausschüttung

11. Sept. 2026

Nächstes Ex-Dividendendatum

21. Aug. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

2.7B

186B

Vorheriger Eröffnungskurs

355.36

Vorheriger Schlusskurs

356.59

Nachrichtenstimmung

By Acuity

36%

64%

104 / 342 Ranking in Healthcare

Amgen Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

24. Juni 2026, 23:01 UTC

Amgen Inc shares are lower in after-market hours, continuing a decline since Wednesday's close. No specific news was identified to explain the movement.

23. Juni 2026, 20:06 UTC

Amgen Inc shares are higher since Monday's close, reaching a session high earlier today. No specific company news was identified to explain the movement.

22. Juni 2026, 19:33 UTC

Biotechnology stocks support Amgen Inc's upward momentum today, with shares higher since Thursday's close despite pulling back from a session high.

18. Juni 2026, 22:06 UTC

Amgen Inc. shares are higher in after-market trading after notable volatility, contrasting with four consecutive lower closes. No specific news was identified for the move.

17. Juni 2026, 19:53 UTC

Macro Event

Amgen Inc. shares are lower today, continuing a trend of declines amid the Federal Reserve's decision to hold interest rates steady.

16. Juni 2026, 19:22 UTC

News

Amgen shares are lower following a jury ruling on patent infringement, despite positive Phase 3 data for Repatha and European approval for Imdylltra.

15. Juni 2026, 21:09 UTC

Amgen Inc shares are trading higher in after-market hours. The broader market is gaining, driven by positive sentiment towards technology stocks and favorable geopolitical news.

12. Juni 2026, 19:51 UTC

News

Amgen Inc. is reassessing data on Tavneos amid FDA scrutiny. Shares are higher as the company challenges the proposal to withdraw the drug's approval.

11. Juni 2026, 23:06 UTC

News

Amgen engages Duke Clinical Research Institute to reassess Tavneos data amid FDA concerns, with shares trading higher in after-market hours.

10. Juni 2026, 23:51 UTC

Amgen Inc. shares declined in after-market trading, continuing a trend of lower daily closes amid rising Treasury yields and weakness in technology stocks.

9. Juni 2026, 19:56 UTC

News

Amgen Inc. shares are lower as Goldman Sachs cuts its price target to $389 from $425 amid an IRS audit disclosure affecting financial outlook.

8. Juni 2026, 20:06 UTC

News

Amgen Inc. shares are lower today after presenting Phase 3 trial results showing Repatha's effectiveness in reducing cardiovascular event risk in high-risk diabetes patients.

5. Juni 2026, 23:01 UTC

Amgen Inc shares are lower in after-market trading amid a broader equity sell-off following stronger-than-expected U.S. non-farm payroll data.

4. Juni 2026, 23:51 UTC

News

Amgen will present at the Goldman Sachs Global Healthcare Conference on June 9, 2026. Shares are trading higher in after-market hours.

3. Juni 2026, 23:41 UTC

Amgen Inc shares are higher in after-market trading, supported by gains in the Biotechnology sub-sector and strong performance above its 20-day moving average.

2. Juni 2026, 23:02 UTC

Amgen Inc. shares are lower in after-market trading, continuing a trend of declines over the last three sessions and remaining below the 20-day moving average.

1. Juni 2026, 20:02 UTC

Amgen Inc. shares are lower today, dropping below Friday's close and nearing the lower end of their one-month trading range. No specific news was identified.

29. Mai 2026, 20:06 UTC

Amgen Inc's shares are higher today, reflecting a slight gain since Thursday's close. The stock remains stable within its one-month trading range.

28. Mai 2026, 23:56 UTC

Amgen Inc's shares are higher in after-market hours, maintaining stability above the 20-day moving average and within the one-month trading range.

27. Mai 2026, 23:01 UTC

Amgen Inc shares are higher in after-market trading, influenced by broader market dynamics, including declining US Treasury yields and inflation concerns.

26. Mai 2026, 19:56 UTC

News

Amgen Inc. shares are lower as rising bond yields reflect inflationary pressures. Analysts maintain a positive outlook on the company's drug pipeline and capital allocation.

22. Mai 2026, 20:06 UTC

News

Amgen Inc. is trading higher amid scrutiny of its rare disease therapy, Tavneos, linked to patient deaths and regulatory restrictions on new prescriptions.

21. Mai 2026, 19:13 UTC

News

Amgen Inc shares rose after Japan allowed new prescriptions for a rare-disease drug, reversing a previous recommendation linked to reported deaths.

20. Mai 2026, 19:51 UTC

News

Amgen Inc. shares are higher following the appointment of Thomas Dittrich as CFO and strong revenue growth of 12.3% over the past two years.

19. Mai 2026, 20:03 UTC

News
Social Media

Amgen Inc. shares are trading higher as analysts express optimism about revenue growth through 2027, despite a price target reduction to $427.

18. Mai 2026, 19:52 UTC

Social Media
News

Amgen Inc shares are lower as safety concerns over Tavneos intensify. Kissei Pharmaceutical advised caution after reports of 20 deaths linked to the drug.

15. Mai 2026, 23:26 UTC

Social Media

Amgen Inc shares are higher in after-market trading, despite social media concerns over recent decisions and a warning from Kissei Pharmaceutical regarding a rare drug.

14. Mai 2026, 19:16 UTC

News

Amgen shares are lower as Piper Sandler cuts price target to $427 from $432. The stock is trading within its one-month range.

13. Mai 2026, 23:02 UTC

Amgen Inc. shares are trading lower in after-market hours, following unusual activity earlier in the session and remaining below the 20-day moving average.

Peer-Vergleich

Kursveränderung

Amgen Inc Prognose

Kursziel

By TipRanks

1.69% Vorteil

12-Monats-Prognose

Durchschnitt 357.38 USD  1.69%

Hoch 427 USD

Tief 300 USD

Basierend auf 24 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Amgen Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

24 ratings

10

Buy

13

Halten

1

Sell

Stimmung

By Acuity

104 / 342 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
help-icon Live chat